OBJECTIVE: To compare the long-term effects of three different programs including initial 6 weeks (V)LCD diets 420 kcal/d, 530 kcal/d, 880 kcal/d) on sustained weight loss, attrition and obesity associated conventional cardiovascular risk factors. DESIGN: Prospective, randomized clinical 52 weeks trial. Two weeks of a booster (V)LCD period after week 26. SETTING: University outpatient obesity clinic. SUBJECTS: Ninety-three middle-aged obese patients (30 men), initial mean BMI 38.7 kg/m 2 , age 20±65 y, from the waiting list. MAIN OUTCOME MEASURES: Weight loss pattern, attrition, reported side effects, blood pressure, blood glucose and serum lipid levels. Repeated frequent measurements up to week 26, intermittently up to ®nal measurements at week 52. RESULTS: One year attrition (30±45%), sustained weight loss (8±15% of initial body weight) and changes in obesity associated risk parameters were similar in all three group. Fewer adverse events were reported in the LCD group. CONCLUSION: The results compare favorably with most previous reports of similar design. VLCD (420 kcal or 530 kcal/ d and LCD 880 kcal/d) were equally effective in long term treatment of obesity. The tendency to less side effects with LCD suggests that such preparations deserve further attention.
Introduction
During recent years, very low calorie diets (VLCD) have been extensively studied. These products can effectively and safely reduce body weight with moderate side effects, and there is now agreement about the indications and counterindications for the use of them. 1±3 Generally these VLCD products contain 400±800 calories per day of high quality protein with essential fatty acids, vitamins and minerals added. Nutrilett (Nycomed, Oslo, Norway) is one of the produces which has been studied during the last years. 4 The recommended daily amount of this product contains 420 kcal with 61 g of protein.
During recent years the optimal energy level and composition of safe and effective VLCD preparations have been discussed, as con¯icting results from studies comparing products with different caloric levels have been published. Several earlier studies suggest that weight loss is similar with VLCD products varying in daily energy content, but the underlying explanation for this paradox remains unresolved. 5±7 New guidelines regulating dietetic products for weight reduction are underway in the Nordic countries as well as in the European community. These changes prompted the following study comparing the well-established 420 kcal Nutrilett with two new versions, a VLCD preparation of 530 kcal per day as well as a low calorie diet (LCD) preparation of 880 kcal per day.
Patients
The patients were recruited from the waiting list of the obesity unit at the Karolinska Hospital, Stockholm, ful®lling conventional and established criteria for VLCD treatment.
1±3 They all had BMI b 30 kg/m 2 , were between the ages 20 and 65 and reported stable weights within the last two months. Both men and women were eligible for study. Exclusion criteria followed conventional recommendations.
Patients with arrhythmias, coronary artery disease, liver disease, gout, porphyria or diabetes mellitus type I were excluded as were patients with eating disorders, psychiatric diseases and alcohol abuse. No pregnant or breast feeding women were included. Subjects on a continuous vegetarian diet and those with a history of lactose intolerance were not invited.
Concomitant medication was recorded throughout the trial. Patients on continuous stable medication for chronic conditions such as treated hypothyroidism or hypertension were not excluded from the trial.
Methods
After giving informed consent to participate in the trial, patients were randomly allocated to three different treatment groups, starting with 6 weeks of either Nutrilett 420 kcal/d, VLCD 530 kcal/d or LCD 880 kcal/d. All patients were informed in detail about the design of the program, the time needed to attend sessions, the dietary instructions etc. Height was recorded initially to the nearest cm. Body weight (kg, on a regularly calibrated scale to the nearest 0.1 kg), waist-hip ratio and sagittal diameter (cm) were measured weekly during the ®rst six weeks of treatment and from then biweekly up to week 52 according to the routine of the unit. After week 28, measurement appointments were purposely made more¯exible to facilitate participation, not all subjects taking part in each session. Body composition was measured by bioimpedance before and after six weeks of treatment and again after 14, 26 and 28 weeks (Standard singe frequency tetrapolar (50 kHz) instrument, TVI-10, Danninger Medical, Columbus, Ohio, USA). Routine safety parameters (haemoglobin concentration, erythrocyte and leukocyte counts and sedimentation rate, fasting blood glucose, serum cholesterol and triglycerides, electrolytes, urate and urinary tests of albumin and glucose) were monitored before treatment, and after 6 and 26 weeks according to the hospital routine as well as supine systolic and diastolic blood pressures with large sized cuffs. During the (V)LCD periods, urinary ketones were checked semiquantitatively three times a week, and (V)LCD patients not showing ketone bodies (4± 16 mmol/l) were asked in detail about possible reasons for noncompliance. On each visit all patients were asked for adverse events following a check list.
After the six weeks of treatment with VLCD or LCD the patients were gradually switched over to a balanced hypocaloric diet (1600 kcal/day) and supervised in group sessions by a research nurse and a dietician. During this seventh week solid foods were gradually introduced in small portions, starting with ®sh, chicken and easily digested vegetables. In addition to this diet, patients were given the general advice and behaviour modi®cation recommendations that form the treatment bases of all long-term programs in addition to VLCD treatment in the Karolinska Hospital obesity unit, as described in detail. 8 After 26 weeks, the patients were again given the same VLCD or LCD preparation for another two weeks as a booster session. From clinical experience with VLCD diets 8 we had the impression that such an additional short term (V)LCD program improves adherence and motivation at a time when body weight loss generally has levelled off in most programs. After another dietary transitional period the patients were then monitored in a more¯exible program with continuous behavioural instructions and reinforcement of a balanced hypocaloric diet, again containing about 1600 kcal/d in group sessions up to 52 weeks. No formal physical activity was organised in the unit, but patients were encouraged to walk and use ample opportunities for regular leisure time physical activity, but this activity was not systematically monitored.
Patients were randomly allocated to one of three hypocaloric treatment programs, but for several practical reasons (different appearance of the preparations and double-dummy not possible) the products could not be blinded. The reference treatment was Nutrilett 420 kcal/day, provided as sachets in water, spread over ®ve meals together with one multivitamin table and one ®sh-oil capsule (9 kcal). The VLCD preparation 530 kcal/day and the LCD 880 kcal/day contained the same ingredients and proportions but with a higher energy content and with the vitamins, minerals and essential fatty acids incorporated into the powder. The main ingredients of all products were based on soy protein and skimmed milk powder. All patients were instructed to use the product with either hot or cold water and to drink at least 2±3 litres of non-caloric uid per day.
Statistical methods
The main variables were weight reduction and safety parameters after 6 and 26 weeks respectively. From earlier studies the mean weight reduction after 8 weeks of Nutrilett treatment was found to be 12 AE 4.5 kg (s.d.). 4 To discover a true difference of 4 kg in weight reduction with a least a chance of 80%, a minimum of 27 patients in each group were required, based on the assumption of a signi®cance level of 1.7% (5%/3) due to the multiple test situation. With an expected drop-out during this time period of 10% about 90 patients were considered necessary.
Weight reduction was analysed by ANOVA with treatment x sex in the model. Tests were two-sided with a conventional signi®cant level at 5%.
All patients gave their informed consent to participate in the study which was approved by the Ethics Committee of the Karolinska Hospital.
Results
Clinical data of the three groups are summarized in Table 1 . In the 420 kcal group 12 patients were on regular medication (cardio-vascular manifestations 5, analgetics 3, hormone treatment 4, H 2 -blocker 1). The corresponding ®gures in the 530 kcal group were 15 patients: cardio-vascular 4, analgetics 6, hormone treatment 3, asthma medication 2, H 2 -blocker 2 and peroral antidiabetics 1. In the 880 kcal group 9 patients were on regular medication: 5 for cardio-vascular problems, 3 for asthma, 2 on thyroxine hormone replacement and 1 on estrogen. Minor changes in medication (dose change, stopped treatment) occurred in 7 cases.
The groups were similar in initial mean body weight, age and sex distribution. The mean weight reduction for the completers throughout the trial is summarised in Table 2 and Figure 1 . After one year of treatment 70% of the patients in VLCD 420 kcal/day, 59 in the VLCD 530 kcal/day and 55% in the LCD 880 kcal/day remained. At no time throughout the study was there any difference in absolute or percentage weight loss or body fat percent between the three groups. Likewise, mean waist and hip circumferences as well as waist/hip ratios and sagittal diameter changes were similar throughout the study (Table 2) . In all compliant patients, urinary ketones were found, also in the LCD group, but in lower concentrations, generally not exceeding 4 mmol/l. Men tended to have higher urinary concentrations of urinary ketones than women.
Data based on intention-to-treat analyses (missing values substituted) show the same pattern, for example a mean sustained weight reduction after 52 weeks of 12.9, 11.2 and 10.0 kg respectively. Safety para- Figure 1 Mean weight loss in completers of (V)LCD treatment combined behavioural modi®cation for one year. No statistically signi®cant group differences at any time. Mean values up to week 28 week 52 based on data from all completers (n 21, 19 and 17 in the 420, 530 and 880 kcal groups), mean values from week 30±50 based on data from at least 14, 10 and 8 measurements respectively meters mainly showed changes within the normal reference limits. In all three groups the expected reduction of fasting blood glucose values, serum lipids and systolic and diastolic blood pressures was observed in relation to the weight loss (Table 3 ). In the 420 kcal group one abnormal ECG was found before treatment, which remained unchanged throughout the trial. In the 530 kcal group minor ECG abnormalities were noted in 4 patients before treatment and in one afterwards. In the 880 kcal group 2 ECG abnormalities were found before and 3 after therapy. Adverse events were mild and generally transient with a tendency for a lower incidence of reported adverse events in the LCD group (a total of 110 reported) compared to the two VLCD groups (a total of 136 (420 kcal/d) and 121 (530 kcal/d) reported). Coldness (81 reports), gastrointestinal discomfort (79), dizziness (75) and headache (64) were the most common adverse effects, but did not warrant withdrawal. Transient alopecia was reported by 16 patients on 420 kcal, 14 patients on 530 kcal and 7 patients on 880 kcal. The intensity was graded mild, moderate and severe. Only one patient in the 420 kcal and one in the 880 kcal group reported such transient severe alopecia.
Discussion
This study con®rms numerous previous reports that sustained long term weight loss can be safely achieved with initial VLCD and LCD preparations 4±8 and that in our completers a 8±15% sustained weight loss can be achieved after one year of treatment with 30±45% attrition. These results compare favorably with most previous similar reports. Furthermore we have demonstrated that a doubling of the daily energy content from the initial 420±880 kcal/d does not result in any difference in weight loss over a one year treatment period. In this respect it supports a study of similar design, suggesting no advantage in using VLCDs which provide less than 800 kcal/d. 9 Although numerous studies have demonstrated the safety of VLCD preparations in the 400±800 kcal/d range as reviewed in other reports, 1±5 it is reasonable to assume that a higher daily intake with a LCD preparation offers a still higher degree of safety. This means that additional patient groups may be included in LCD treatment who may not be primarily considered for VLCD for safety reasons. As demonstrated by this study, patients tended to report fewer adverse effects in the LCD group, although this did not result in a statistically signi®cantly higher compliance. The fact that also patients during the LCD period exhibited measurable levels of urinary ketone bodies suggests that even at these energy intake levels, ketonemia develops and can be used as a practical tool in assessing compliance.
In the design of responsible treatment strategies for VLCD treatment, physician supervision is encouraged, 1 although we and other authors have demonstrated that this may not be necessary. 10, 11 In most (V)LCD studies carried out at the obesity unit of the Karolinska Hospital, a well-trained nurse has been responsible for the treatment program with a physiotherapist and a dietician available for occasional advice in group sessions and with a physician available but not routinely involved in the treatment unless complications or questions appear. However, our treatment programs lasted for only six weeks, whereas many other programs where supervision by a physician has been considered essential, run over 12±16 weeks.
The incorporation of a two week VLCD-or LCDperiod after half a year was considered most helpful by the patients who at that time often feel that motivation goes down as weight loss does not occur any longer. In many programs of this design a nadir in weight loss is observed at this time and we have had the empirical experience that any kind of booster activity improves program attendence, as is also evidenced by the fact that the study demonstrates overall good weight loss in reasonably compliant obese patients. In summary, we conclude that VLCD (420 or 530 kcal/d) and LCD (880 kcal/d) preparations were equally effective in reducing body weight as an initial part of a long-term treatment program. The tendency to a lower incidence of reported adverse events with the same weight loss maintenance suggest that LCD preparations deserve further attention
